EE04391B1 - Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid - Google Patents

Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid

Info

Publication number
EE04391B1
EE04391B1 EEP200000589A EEP200000589A EE04391B1 EE 04391 B1 EE04391 B1 EE 04391B1 EE P200000589 A EEP200000589 A EE P200000589A EE P200000589 A EEP200000589 A EE P200000589A EE 04391 B1 EE04391 B1 EE 04391B1
Authority
EE
Estonia
Prior art keywords
superlaggregates
tablets
formulations
making
methods
Prior art date
Application number
EEP200000589A
Other languages
English (en)
Estonian (et)
Inventor
T. Makooi-Morehead William
D. Buehler John
R. Landmann Brian
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04391(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE200000589A publication Critical patent/EE200000589A/xx
Publication of EE04391B1 publication Critical patent/EE04391B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000589A 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid EE04391B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (2)

Publication Number Publication Date
EE200000589A EE200000589A (et) 2002-04-15
EE04391B1 true EE04391B1 (et) 2004-12-15

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000589A EE04391B1 (et) 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid

Country Status (27)

Country Link
US (2) US6238695B1 (xx)
EP (1) EP1067936B1 (xx)
JP (1) JP2002510634A (xx)
KR (1) KR100634253B1 (xx)
CN (1) CN1146419C (xx)
AR (1) AR019031A1 (xx)
AT (1) ATE223719T1 (xx)
AU (1) AU756422B2 (xx)
BR (1) BR9908810A (xx)
CA (1) CA2321523C (xx)
CZ (1) CZ300850B6 (xx)
DE (1) DE69902893T2 (xx)
DK (1) DK1067936T3 (xx)
EA (1) EA003217B1 (xx)
EE (1) EE04391B1 (xx)
ES (1) ES2181417T3 (xx)
HU (1) HU228498B1 (xx)
IL (1) IL138078A (xx)
NO (1) NO325824B1 (xx)
NZ (1) NZ507566A (xx)
PL (1) PL194309B1 (xx)
PT (1) PT1067936E (xx)
SK (1) SK284655B6 (xx)
TW (1) TW576741B (xx)
UA (1) UA72207C2 (xx)
WO (1) WO1999051239A1 (xx)
ZA (1) ZA200004313B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
KR20070040426A (ko) * 1998-06-11 2007-04-16 파마시아 앤드 업존 캄파니 엘엘씨 빠르게 침전하는 약물의 정제 제제
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
EP1448170A4 (en) * 2001-11-27 2010-05-12 Bristol Myers Squibb Co EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040224916A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8021682B2 (en) * 2004-08-13 2011-09-20 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
AU2006325404B2 (en) * 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
MX2009002873A (es) * 2006-09-14 2009-05-19 Chemlink Lab Llc Metodo para preparar formas de dosis solida que forman una pasta, crema o gel cuando se diluyen para uso final.
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
JP2010536798A (ja) * 2007-08-17 2010-12-02 テバ ファーマシューティカル インダストリーズ リミティド 難溶性薬物の生体利用率を制御するための方法及び組成物
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
NZ627826A (en) 2010-01-27 2016-01-29 Viiv Healthcare Co Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
NZ602955A (en) * 2010-04-20 2015-02-27 Cipla Ltd Pharmaceutical composition comprising efavirenz
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
IN2013MU03370A (xx) 2013-10-25 2015-09-25 Cipla Ltd
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017029226A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7084587A (en) 1986-04-01 1987-10-20 Upjohn Company, The Methylprednisolone/sodium carboxymethyl starch tablet composition
CA2002137A1 (en) * 1989-04-28 1990-10-28 Genkichi Ohta Anti-human immunodeficiency virus composition
DK0577913T3 (da) * 1992-07-08 1998-01-26 Santen Oy Ophthalmisk præparat indeholdende timolol-hemihydrat
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz

Also Published As

Publication number Publication date
AU756422B2 (en) 2003-01-09
PL343421A1 (en) 2001-08-13
SK284655B6 (sk) 2005-08-04
BR9908810A (pt) 2000-12-19
AU3463799A (en) 1999-10-25
NO20005043L (no) 2000-10-06
US20010012518A1 (en) 2001-08-09
DE69902893D1 (de) 2002-10-17
IL138078A0 (en) 2001-10-31
CN1146419C (zh) 2004-04-21
EE200000589A (et) 2002-04-15
CA2321523C (en) 2008-10-07
HUP0101517A3 (en) 2002-11-28
ZA200004313B (en) 2002-01-30
NZ507566A (en) 2002-11-26
WO1999051239A1 (en) 1999-10-14
EP1067936B1 (en) 2002-09-11
KR20010042473A (ko) 2001-05-25
ATE223719T1 (de) 2002-09-15
SK14612000A3 (sk) 2001-07-10
US6555133B2 (en) 2003-04-29
KR100634253B1 (ko) 2006-10-16
TW576741B (en) 2004-02-21
JP2002510634A (ja) 2002-04-09
HUP0101517A2 (hu) 2001-11-28
CN1296412A (zh) 2001-05-23
CA2321523A1 (en) 1999-10-14
DE69902893T2 (de) 2003-04-30
ES2181417T3 (es) 2003-02-16
EA200001030A1 (ru) 2001-04-23
CZ20003571A3 (cs) 2001-01-17
IL138078A (en) 2005-12-18
PL194309B1 (pl) 2007-05-31
US6238695B1 (en) 2001-05-29
CZ300850B6 (cs) 2009-08-26
HU228498B1 (en) 2013-03-28
EP1067936A1 (en) 2001-01-17
NO20005043D0 (no) 2000-10-06
DK1067936T3 (da) 2003-02-17
UA72207C2 (uk) 2005-02-15
NO325824B1 (no) 2008-07-21
PT1067936E (pt) 2002-12-31
AR019031A1 (es) 2001-12-26
EA003217B1 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
EE04391B1 (et) Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid
NO996433D0 (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
NO971485D0 (no) Antineoplastiske kakaoekstrakter, metoder for fremstilling og anvendelse
NO20004643D0 (no) Polymerbaserte raskt oppløselige tabletter og fremgangsmÕte for fremstilling derav
DK1112266T3 (da) Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
IS5662A (is) Þíenýlasólýlalkoxýetanamín, framleiðsla þeirra ognotkun sem lyf
NO20032332D0 (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
IS2821B (is) Amínóalkýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20015659L (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
HK1044156A1 (en) Camptothecin analogs and methods of preparation thereof.
DK1131052T3 (da) Vaginalt indgivelige progesteron-holdige tabletter og fremgangsmåde til fremstilling deraf
PL350902A1 (en) Pyridothiene diazepins, method of obtaining them and pharmacological compositions containing them
PL342453A1 (en) Biphenylsulphonylcyanamides, method of obtaining them and their application as drugs
ZA99168B (en) Pharmaceutical formulations and processes for their preparation.
HUP0102116A3 (en) Paroxetine ascorbate, process for its preparation and its pharmaceutical use
DK1076651T3 (da) Substituerede sulfonylcyanamider, fremgangsmåde til fremstilling heraf og anvendelsen heraf som lægemidler
SI1067936T1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
DK1259523T3 (da) Pluraflaviner og derivater deraf, fremgangsmåde til fremstilling og anvendelse deraf
PL332894A1 (en) Hadgehog protein conjugate, method of obtaining same, pharmaceutic composition and method of obtaining same, hedgehog protein
EE200100474A (et) Antratsükliinide L-arabinodisahhariidid, nende valmistamise meetodid ning neid sisaldavad ravimkoostised
DK1047668T3 (da) Triazepinoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf
DZ3065A1 (fr) Formulations pour la toux à base de plantes médicinales et procédés pour leur préparation.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231